Drugs / DLBS1425
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01006785 | Aug 2009 → Mar 2012 | breast cancer | Dexa Medica Group | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01433562 | Aug 2011 → Nov 2012 | breast cancer | Dexa Medica Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLBS1425 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01006785 ↗ |
| Route | Oral | “DLBS1425 capsules will be administered orally every day” NCT01433562 ↗ |